| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biophys J, June 2000, p. 2733-2734, Vol. 78, No. 6
The Johnson Foundation, Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, Pennsylvania 19104 USA
Many progressive neurodegenerative diseases
including Huntington's disease, spinobulbar muscular
atrophy, dentatorubral pallidoluysian atrophy, and spinocerebellar
ataxia types 1, 2, 3, 6, and 7 are caused by an expansion of CAG
(polyglutamine) codons at the ends of genes coding for various proteins
(reviewed in, e.g., Reddy and Housman, 1997 At the heart of this hypothesis is a novel protein structure, the
µ-helix, predicted to be stable only for polyglutamine
sequences (Monoi, 1995 Given that such a structure, albeit never observed in protein solution
or crystal structures, is possible, Monoi and coworkers then set about
to determine experimentally if polyglutamine could make ion channels.
Because polyglutamine peptides are virtually impossible to purify to
homogeneity, the authors compared two samples that had been prepared
and partially purified in the same way, but which contained peptides of
29 versus 40 residues maximum length. Only the sample containing the
longer peptides made ion channels in multiple, well-controlled planar
bilayer experiments. Moreover, the observed channels had the
well-defined unit conductances characteristic of stable ion channel
structures, rather than the erratic conductance fluctuations often
observed with membrane-perturbing protein fragments and peptide toxins
such as melittin. Strikingly, the channels were small,
cation-selective, and only very weakly rectifying, all properties
one might predict from the µ-helix structure.
Where might this work lead? Certainly, it should inspire efforts to
make and characterize µ-helix structures in smaller, soluble polyglutamine peptides (see, e.g., Perutz et al., 1994 The challenge of biophysics has always been to find, in the complex
processes observed in living systems, relatively simple underlying
physical mechanisms. This class of devastating, incurable illnesses
presents this challenge in the very urgent context of human medicine,
and Monoi and coworkers are to be commended for a creative and
inventive effort in addressing it.
![]()
INTRODUCTION
TOP
INTRODUCTION
REFERENCES
). In every case except the
type 6 ataxia, which involves a defective calcium channel (Lunkes and
Mandel, 1997
), expansions of up to about 35 residues are benign,
whereas expansions of >40 residues are pathogenic. Perutz (1999)
has
hypothesized that sufficiently long glutamine repeats can form hairpin
structures that destabilize proteins and produce insoluble aggregates.
The presence of protein aggregates inside afflicted neurons is, in fact, a post-mortem diagnostic marker of these diseases (Lunkes et al.,
1998
). However, it is not known whether the aggregates themselves are
pathogenic or are, instead, by-products of other cellular processes.
Recent work with yeast, for example, has shown that aggregated
fragments of polyglutamine-expanded huntingtin protein, the causative
factor in Huntington's disease, are not particularly toxic to cells
expressing them (Krobitsch and Lindquist, 2000
). Also, Saudou et al.
(1998)
found that inhibiting ubiquination and consequent formation of
aggregates in the cell nucleus increased rather than decreased the
toxic effect of polyglutamine-expanded huntingtin expressed in
transfected striatal neurons. Although the evidence linking glutamine
expansion length with both disease and protein aggregates is clear and
abundant, a mechanistic relationship between protein aggregation and
cellular toxicity has yet to be established. In this issue of the
Biophysical Journal, Monoi et al. (2000)
provide evidence in
support of a strikingly simple and direct alternative to the
aggregation hypothesis to explain the length dependence of
polyglutamine toxicity: only repeats greater than 40 residues are long
enough to form membrane-depolarizing ion channels in cells.
). This structure is remarkable in that a single, all L-amino acid polypeptide chain forms a helix with a 3.7 Å diameter
cylindrical pore along its axis, physically large enough to accommodate
passage of small ions and water. In the helix, each residue adds only
about 0.81 Å to the length, so spanning 30 Å of bilayer hydrocarbon
requires at least 37 residues instead of the 20 required for an
-helix. The interior of the pore is lined with backbone amide and
carbonyl groups, much like gramicidin. The exterior surface of the pore
is made up of glutamine side chains whose amide carbonyls form hydrogen
bonds to side chain amide NH2 groups 6 residues
away toward the peptide's amino terminus. These hydrogen bonds,
together with those of the oppositely directed backbone amide hydrogen
bonds, presumably provide sufficient energy to stabilize an otherwise
energetically improbable structure. Ordinarily, one might dismiss the
suggestion that an ion channel structure has polar glutamine
residues exposed to bilayer hydrocarbon. However, Monoi et al. (2000)
point out that the hydrogen bonding of glutamine's side chain amides
significantly reduces their unfavorable free energy of transfer to the
hydrocarbon, so bilayer insertion is not implausible.
), as well as
to confirm and extend the present ion channel study to a wider range of
glutamine repeat lengths. In addition, there are many questions to be
answered about how polyglutamine repeats might produce cell-specific
toxic effects in vivo. Does insolubility precede, parallel, or follow
ion channel formation? Could it be that certain membrane lipid
compositions are more susceptible than others, similar to the tropism
observed with some natural peptide toxins? Are other proteins involved
in the process? Might these small, probably sparse channels cause slow
neuronal death by chronically overtaxing already highly active
ATP-dependent ion pumps?
| |
FOOTNOTES |
|---|
Received for publication 10 April 2000 and in final form 12 April 2000.
Address reprint requests to Dr. James D. Lear, Department of Biochemistry and Biophysics, The Johnson Foundation, School of Medicine, 36th and Hamilton Walk, University of Pennsylvania, Philadelphia, PA 19104-6059. Tel.: 215-898-2071; Fax: 215-898-4217; E-mail: lear{at}mail.med.upenn.edu.
| |
REFERENCES |
|---|
Biophys J, June 2000, p. 2733-2734, Vol. 78, No. 6
© 2000 by the Biophysical Society 0006-3495/00/06/2733/02 $2.00
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |